Among patients with active cancer and acute symptomatic VTE , the use of full-dose tinzaparin ( @ IU/kg ) daily compared with warfarin for @ months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding , but was associated with a lower rate of clinically relevant nonmajor bleeding .